---

---

treatment   publishing date : 2023 - 01 - 25   

save search

---

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
Published: 2023-01-25 (Crawled : 23:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -6.17% | O: -0.96% H: 0.0% C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M |

Health Technology

| -6.53% | O: 0.89% H: 0.0% C: 0.0%
treatment potential

---

Macerich Announces Tax Treatment Of 2022 Dividends
Published: 2023-01-25 (Crawled : 22:00) - prnewswire.com
MAC | $15.17 -1.3% 0.0% 1.7M |

Finance

| 18.05% | O: 0.54% H: 1.45% C: 1.38%
treatment dividends

---

UMH PROPERTIES, INC. ANNOUNCES TAX TREATMENT FOR 2022 DISTRIBUTIONS
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
UMH 4 | $15.24 0.46% -0.13% 170K |

Finance

| -10.24% | O: 0.24% H: 0.94% C: 0.77%
treatment

---

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
ARDS | $0.0615 -6.82% 2.82% 410K |

Health Technology

| -95.12% | O: -25.2% H: 2.17% C: -13.04%
ar-301 treatment trial staphylococcus aureus

---

Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
Published: 2023-01-25 (Crawled : 17:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.14% 3.6M |

Health Technology

| 11.83% | O: -0.21% H: 0.41% C: 0.28%
education medical symposium aesthetic

---

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
CMND | $1.1781 -1.0% 0.83% 36K |

n/a

| -69.44% | O: 6.31% H: 12.35% C: -7.36%
JNJ | News | $145.74 0.67% -0.18% 7M |

Health Technology

| -13.88% | O: -0.68% H: 1.4% C: 1.4%
treatment obesity biotech

---

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
Published: 2023-01-25 (Crawled : 14:00) - ir.pulmatrix.com
PULM | $1.96 -6.22% -7.18% 31K |

Health Technology

| -42.58% | O: -2.47% H: 15.77% C: 12.96%
pur3100 treatment potential

---

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
Published: 2023-01-25 (Crawled : 14:00) - globenewswire.com
ATNF | $1.83 -4.19% 0.0% 90K |

| -53.31% | O: 15.77% H: 45.78% C: 15.53%

---

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
VERA | $39.48 -1.33% -1.27% 860K |

Professional, Scientific, and T...

| 337.75% | O: -0.33% H: 1.1% C: -0.55%
treatment nephropathy therapeutics igan

---

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
ELOX | $0.94 -2.34% -51.57% 93K |

Health Technology

| -77.51% | O: -0.48% H: 6.97% C: 2.64%
elx-02 treatment pharmaceuticals study phase 2

---

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-25 (Crawled : 13:00) - biospace.com/
ATHE | $2.14 6.47% 6.51% 27K |

Health Technology

| -44.85% | O: -2.06% H: 5.66% C: 2.63%
ath434 treatment system trial therapeutics phase 2

---

Lupin Pharma Canada announces the availability of Intrarosa (prasterone vaginal ovules), a new treatment option in Canada for women with postmenopausal vulvovaginal atrophy
Published: 2023-01-25 (Crawled : 13:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| 30.51% | O: -3.2% H: 0.0% C: 0.0%
treatment pharma women canada

---

ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
Published: 2023-01-25 (Crawled : 13:00) - prnewswire.com
ANVS | $9.85 9.57% 1.52% 240K |

Health Technology

| -21.45% | O: 6.62% H: 0.0% C: -5.09%
treatment disease parkinson's buntanetap update study

---

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Published: 2023-01-25 (Crawled : 12:00) - globenewswire.com
CDTX | $0.722 -0.03% -0.29% 270K |

Health Technology

| -22.42% | O: 15.29% H: 21.5% C: 19.63%
treatment fda candidiasis approval therapeutics rezafungin candidemia

---

Fracking water treatment market size to increase by USD 1,208.4 million: Market research insights highlight the increasing consumption of natural gas as a key driver - Technavio
Published: 2023-01-25 (Crawled : 03:00) - prnewswire.com
XYL | $127.16 0.75% -0.91% 910K |

Producer Manufacturing

| 21.87% | O: -1.1% H: 0.59% C: 0.11%
AQUA | $49.88 0.0% 31M |

Industrial Services

| 5.33% | O: 0.77% H: 0.0% C: 0.0%
water treatment research natural market

---

Gainers vs Losers

60%

40%

Top 10 Gainers

AGBA | News | $1.03 157.5% 57.94% 120M |

Finance

ZCMD | $1.45 5.84% 52.1% 2.3M |

Commercial Services

INVO | $1.52 100.0% 51.13% 5M |

Health Technology

ISPC | $0.421 97.65% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.5 45.65% 470K |

OST | $0.509 23.81% 45.26% 90K |

GDHG | $0.263 21.76% 40.66% 3.1M |

XPON | News | $3.15 63.21% 37.74% 16M |

TIRX | $0.8 65.02% 30.74% 58M |

BNTC | News | $6.82 42.08% 30.64% 3.5M |

Health Technology

---

Your saved searches

---